What is imatinib-resistant chronic myeloid leukemia? Identifying and managing loss of response

Area of Science:

• Hematology
• Oncology
• Pharmacology

Background:

• Imatinib is the standard first-line therapy for chronic myeloid leukemia (CML).
• Treatment resistance can limit the long-term efficacy of imatinib.
• Early identification of response loss is vital for optimal patient management.

Purpose of the Study:

• To emphasize the importance of early response monitoring in imatinib-treated CML patients.
• To highlight predictive markers for long-term outcomes.
• To guide treatment strategy modifications in cases of suboptimal response or resistance.

Main Methods:

• Analysis of cytogenetic and molecular responses within the first 12 months of imatinib therapy.
• Evaluation of early BCR-ABL level reduction as a predictive indicator.
• Consideration of kinase domain mutation monitoring in resistant cases.

Main Results:

• Early cytogenetic and molecular responses predict future complete cytogenetic response and major molecular response.
• The degree of early BCR-ABL reduction correlates with subsequent treatment response.
• Monitoring mutations is recommended for patients with suboptimal response or resistance.

Conclusions:

• Early response assessment in CML patients treated with imatinib is critical for predicting long-term outcomes.
• Timely monitoring of BCR-ABL levels and mutations can guide treatment adjustments.
• Effective management of CML requires proactive monitoring and potential modification of therapy.